Can Rapport Therapeutics, Inc. cover its short-term obligations?

Its current ratio is 27.08 — current assets exceed current liabilities.

Where does Rapport Therapeutics, Inc.'s balance sheet data come from?

Every line is extracted from Rapport Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Rapport Therapeutics, Inc. RAPP Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23
Cash and cash equivalents	$52.65M-7.3%	$56.81M-19.0%	$70.17M—
Short-term investments	$437.89M+76.2%	$248.48M+221%	$77.31M—
Restricted cash	$105K0.0%	$105K+23.5%	$85K—
Accounts receivable, net	——	——	——
Prepaid expenses and other current assets	$7.92M+79.2%	$4.42M+33.5%	$3.31M—
Total current assets	$498.56M+60.9%	$309.8M+105%	$150.87M—
Property and equipment, net	$2.98M-15.7%	$3.53M+84.2%	$1.92M—
Operating lease right-of-use assets	$9.91M+587%	$1.44M-30.8%	$2.08M—
Other non-current assets	$985K+516%	$160K-71.0%	$551K—
Total assets	$512.43M+62.7%	$314.93M+103%	$155.42M—
Accounts payable	$12.74M+217%	$4.02M—	——
Accrued expenses	$12.1M+99.2%	$6.08M+7.9%	$5.63M—
Operating lease liabilities, current	$2.76M+274%	$737K+10.0%	$670K—
Total current liabilities	$19.05M+117%	$8.77M-0.4%	$8.8M—
Operating lease liabilities, non-current	$8.73M+1,081%	$739K-49.9%	$1.48M—
Operating Lease Liabilities (Total)	$11.48M+678%	$1.48M-31.2%	$2.15M—
Total liabilities	$27.78M+192%	$9.51M-34.3%	$14.48M—
Preferred stock	$0—	$0—	$0—
Common stock	$48K+29.7%	$37K+825%	$4K—
Additional paid-in capital	$719.29M+67.4%	$429.66M+2,070%	$19.8M—
Retained earnings	-$235.23M-90.1%	-$123.75M-172%	-$45.44M—
Accumulated other comprehensive income (loss)	$546K+205%	-$522K-13,150%	$4K—
Total stockholders' equity	$484.65M+58.7%	$305.43M+1,291%	-$25.63M-155%
Total liabilities and stockholders' equity	$512.43M+62.7%	$314.93M+103%	$155.42M—
Deferred Tax Assets and Other Non-Current Assets	$985K+516%	$160K-71.0%	$551K—
Net Investment in Lease	$9.91M+587%	$1.44M-30.8%	$2.08M—
Operating lease right-of-use assets	$9.91M+587%	$1.44M-30.8%	$2.08M—
Other non-current assets	$985K+516%	$160K-71.0%	$551K—
Short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84)	$437.89M+76.2%	$248.48M+221%	$77.31M—
Operating Lease Right-of-Use Assets in Other Assets	$9.91M+587%	$1.44M-30.8%	$2.08M—
Software and Technology Licenses, Net	$985K+516%	$160K-71.0%	$551K—
Other Commercial Liabilities	$12.1M+99.2%	$6.08M+7.9%	$5.63M—
Accrued Liabilities, Current	$12.1M+99.2%	$6.08M+7.9%	$5.63M—
Total debt	$11.48M+678%	$1.48M-31.2%	$2.15M—
Additional paid-in capital	$719.29M+67.4%	$429.66M+2,070%	$19.8M—
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$48K+29.7%	$37K+825%	$4K—
Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding	$0—	$0—	$0—

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Can Rapport Therapeutics, Inc. cover its short-term obligations?: Its current ratio is 27.08 — current assets exceed current liabilities.
Where does Rapport Therapeutics, Inc.'s balance sheet data come from?: Every line is extracted from Rapport Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.